About Careers Internship MedBlog Contact us

Prescribing a High-Dose of Baclofen May Not Be Effective In Treating Alcoholism

  • Baclofen is widely used as a skeletal muscle relaxant.
  • A research team from the University of Amsterdam conducted a largest Randomised Controlled Trial (RCT) to study the use of baclofen for alcoholism.
  • Prescribing a high-dose of baclofen for alcohol dependence should be reconsidered as the drug was found to have only little effect.

Prescribing a High-Dose of Baclofen May Not Be Effective In Treating Alcoholism

Premature use of Baclofen drug to treat alcoholism along with psychosocial treatments has no evidence, finds a recent study from the University of Amsterdam.

Baclofen is a Gaba- b agonist that is widely used as a skeletal muscle relaxant. It is used to relieve muscle cramps, spasms and muscle tightness.

Listen to this article

Since few trials demonstrate baclofen to be useful in treating alcohol dependence and patients too indicate relief. The French authorities in 2014 were asked to allow doctors to prescribe high doses of baclofen for alcohol-dependent patients.

A research team from Netherlands studied the largest randomised controlled trial (RCT) on baclofen for alcoholism.

The report study published in the journal European Neuropsychopharmacology indicated the drug to have little effect when provided with psychosocial treatment.

Baclofen use for alcohol dependence actually originated from 'The end of my addiction', written by the French physician Olivier Ameisen, who asserted to have cured alcohol dependence by administering a high dose of baclofen.

The research study was conducted for 16 weeks on 151 alcoholic patients. Out of which 58 patients received high-dose baclofen (starting with a low dose to 150mg/day), 31 patients low dose baclofen and 62 received placebo.

The research findings at the end of the trial found, no difference in recurrence rate between the two groups. About 25% of people were found to drink alcohol even after treatment.

Reinout Wiers, Professor, University of Amsterdam, said, "This came as a surprise to us. In August 2015 a small German RCT** had indicated that high dose baclofen showed good results, but their control group did not receive any treatment, whereas all our patients, including the placebo group, received psychosocial treatment. Together these studies indicate that baclofen may be as effective as psychosocial care, but does not seem to increase effectiveness further. This means that we may have to further study the effectiveness of baclofen before we can recommend it for use. For example, perhaps it can help a subgroup of alcohol-dependent patients who do not respond to psychosocial treatment. We believe that prescribing baclofen widely, as currently happens in France, might be premature and should be reconsidered".

"We are planning a new RCT, where we will test high dose Baclofen, up to 330 mg per day, in alcohol-dependent patients who have not responded to regular psychological treatment. For comparison, the maximum recommended adult dose of baclofen for its normal (spasticity) use is 80 mg/day. We need to consider safety and side-effects. We are not closing the door on baclofen, but we are saying that we need more research," he added.

According to the Professor Jonathan Chick, Medical Director, Castle Craige Hospital, Edinburg, Scotland, baclofen was found to show promise in patients from Italian liver clinics who did not receive psychosocial treatment. A new dutch study which was based on a 12 step model, patients were recruited from 4 to 6 weeks residential program. The study results found better outcome than the usual European study, Psychosocial treatment was found to provide good results and additional effects of baclofen will not have any notable effects in a group of this size.

It is therefore important that doctors reconsider prescribing baclofen for alcohol dependence.

  1. Esther M. Beraha. et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology ; (2016) http:dx.doi.org/10.1016/j.euroneuro.2016.10.006

Source: Medindia
Font : A-A+

Cite this Article   close



Recommended Readings

Latest Health Watch

AI-Powered Chinese Weight Loss Drug
Chinese scientists utilize artificial intelligence to develop a breakthrough weight-loss drug which also treats type 2 diabetes.
Measles Resurgence: Tackling Viral Outbreak
As compared to previous years, India's capital has seen a sharp increase in measles cases, with 543 cases reported in 2022.
World Contraception Day: Championing Choice and Empowerment
On World Contraception Day, we emphasize the importance of awareness, access, and empowerment. Let's champion informed choices for reproductive health.
Yoga Can Be Therapeutic for Heart Health
Explore how yoga therapy enhances heart health, as revealed in a study by an ICMR expert. Unveil yoga's potential to complement traditional cardiac care.
Pregnancy Diet Essentials Beyond Prenatal Vitamins
Discover the six essential nutrients crucial during pregnancy and how to optimize dietary intake for the well-being of both mother and baby.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Prescribing a High-Dose of Baclofen May Not Be Effective In Treating Alcoholism Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests